Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010;10(2):123-32.
doi: 10.2165/11584530-000000000-00000.

Tremelimumab

No authors listed
Review

Tremelimumab

No authors listed. Drugs R D. 2010.

Abstract

Tremelimumab (CP 675206; CP-675; CP-675,206; CP-675206; Ticilimumab) is a fully human IgG2 anitbody, which is directed against human cytotoxic T lymphocyte-associated antigen 4 (CTLA4). It is being developed by Pfizer for the treatment of various cancers. It is currently in worldwide phase III development for malignant melanoma, phase II development for colorectal cancer, gastrointestinal cancer, gynecological cancer, and non-small cell lung cancer in the US and other countries, and is also being investigated for prostate, breast, and pancreatic cancer in various countries. This review discusses the key development milestones and therapeutic trials of this drug.

PubMed Disclaimer

Figures

Table I
Table I
Features and properties
Table II
Table II
History
Table III
Table III
Forecasts
See this image and copyright information in PMC

References

    1. Pfizer and Debiopharm collaborate to co-develop investigational compound tremelimumab (CP-675,206) in advanced melanoma. 2010.
    1. Medarex Announces Major Antibody Strategic Alliance with Pfizer. 2004.
    1. Chung KY, Gore I, Fong L, et al. A phase II study of the anti-CTLA4 monoclonal antibody, CP-675,206, in patients with refractory metastatic adenocarcinoma of the colon or rectum. J Clin Oncol. 2007;25:126.
    1. Pfizer Announces Discontinuation of Phase III Clinical Trial for Patients with Advanced Melanoma. 2008.
    1. Pfizer Fourth-Quarter and Full-Year 2005 Financial Results Reflect Operating and Financial Strength. 2006.